비소세포폐암에서 Gefitinib 내성 극복을 위한 효과적인 화합물 합성 및 항암 활성 평가

• 영문명: Synthesis of Effective Compounds and Evaluation of Anticancer Activity for Overcoming Gefitinib Resistance in Non-Small Cell Lung Cancer
• 발행기관: 대한약학회
• 저자명: 김광일(Kwang Il Kim) 박소연(So-Yeon Park) 최대옥(Daeock Choi) 김항건(Hangun Kim)
• 간행물 정보: 『약학회지』제68권 제2호(2024년), 94~97쪽, 전체 4쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2024.03.30

영문 초록

Lung cancer remains a leading cause of global cancer-related mortality, emphasizing the need for innovative strategies to combat resistance to the first-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs), Gefitinib. This study aimed to discover and evaluate small molecule compounds selectively inhibiting Gefitinib resistance. A compound library was screened against adenocarcinoma (A549), EGFR-mutant NSCLC (H1975 and PC9), and Gefitinib-resistant NSCLC (PC9GR) cell lines. The study identified W1 as a promising lead compound, and its derivative, compound W3, exhibited excellent efficacy in PC9 and PC9GR cells. These findings underscore the potential of W3, an 4-anilinopyrimidine derivative, as an inhibitor of Gefitinib resistance in NSCLC. This research contributes valuable insights to the ongoing efforts in developing effective and sustainable treatment options for lung cancer patients facing EGFR-TKI resistance.

목차

서 론(Introduction)

방 법(Methods)

결과 및 고찰(Results and Discussion)

결 론(Conclusion)

Conflict of Interest

References

키워드

Lung cancer NSCLC EGFR tyrosine kinase inhibitors EGFR-mutant